Management of peritoneal metastasis from neuroendocrine tumors

Au, Joyce T.; Levine, Jason; Aytaman, Ayse; Weber, Thomas K.; Serafini, Francesco

doi:10.1002/jso.23399

Cited by 7 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For PC arising from colorectal adenocarcinoma, a PCI ≥16 predicts incomplete surgical removal [13]. For NET, the corresponding threshold was estimated to be 20 [14]. The classification of Gilly et al [11] also relies on the size of PC nodules and their localization as assessed intraoperatively, and defines 5 stages from 0 to 4 (table 1).…”

Section: Evaluation Of Pcmentioning

confidence: 99%

“…Notably, those scores are easy to use and reproducible, and seem to evaluate the PC extent appropriately, especially before and after any surgical PC resection to predict its effectiveness [10,14,15]. However, they may no longer be the most relevant, because they require careful intraoperative assessment, and most patients with PC do not undergo surgery.…”

Section: Evaluation Of Pcmentioning

confidence: 99%

“…Although the currently available radiological means (i.e., computed tomography scan, somatostatin receptor scintigraphy and magnetic resonance imaging) are widely used to preoperatively evaluate NET patients with PC, their abilities to evaluate the presence of PC or its extent seem poor, and their relationship to intraoperative evaluation has not yet been explored [16]. Finally, laparoscopic staging might be helpful for the initial PC workup, especially to determine its form, but has never been assessed for digestive NET [14]. Laparoscopy enables the detection of PC and the evaluation of its extent, even when microscopic involvement is not detectable on conventional imaging, and could prevent nontherapeutic open surgical interventions [17,18].…”

Section: Evaluation Of Pcmentioning

confidence: 99%

“…Instinctively, and as underlined by the selection bias in the paper by Elias et al [31], patients with the lowest tumor grades or the less progressive diseases might benefit the most from PC surgery. Moreover, PC surgery should only be considered if CCR could be expected, particularly when the PCI is <20, for GPS-A (grade 0-3) patients and some selected GPS-B (grade 4-6) patients after case-by-case assessment [10,14]. Evaluating the PC form could help distinguish between ‘low' (i.e., nodular PC) and ‘high' (fusiform/infiltrative PC) GPS-B patients.…”

Section: How To Select Net Patients For Pc Surgical Managementmentioning

confidence: 99%

See 3 more Smart Citations

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Well-differentiated digestive neuroendocrine tumors (NET) are a heterogeneous group of neoplasms usually associated with slow growth but a high rate of metastases, including peritoneal carcinomatosis (PC). Herein, we aimed to comprehensively review the current knowledge of PC in terms of implications for the management and prognosis of patients with NET, including the latest studies and expert statements. NET-derived PC concerns about 17% of NET patients and up to 30% of those with small intestine primary NET. It has an independent pejorative prognostic impact. The extent of PC in NET patients and its severity can be expressed by analogy to other malignancies. However, it must be placed in the context of NET disorders, which usually vary from other PC-related malignancies. Recently, a gravity PC score was proposed by a consensus European Neuroendocrine Tumor Society (ENETS) expert group, but it requires validation. In addition, the form of peritoneal involvement (nodular or fusiform/infiltrative) might influence its prognosis and management. Aggressive surgical management seems justified for subsets of NET-related PC but requires careful selection of the candidates most likely to benefit. Cytoreductive surgery prolongs survival, especially when the peritoneal lesions are completely resected. Too little is known about the benefit of hyperthermic intraperitoneal chemotherapy for NET-derived PC, but if it confers an advantage, it would have to be counterbalanced by its high morbidity.

show abstract

Section: Evaluation Of Pcmentioning

confidence: 99%

Section: Evaluation Of Pcmentioning

confidence: 99%

Section: Evaluation Of Pcmentioning

confidence: 99%

Section: How To Select Net Patients For Pc Surgical Managementmentioning

confidence: 99%

See 2 more Smart Citations

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Although it frequently represents an occasional finding during disease staging or follow-up, in some patients it can instead negatively influence quality of life, with deterioration of clinical status. PC can indeed cause recurrent abdominal pain or even bowel obstruction, with bloating, nausea, and vomiting as additional clinical presentation and need of surgery in a subgroup of patients [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options

et al. 2019

View full text Add to dashboard Cite

Background: Peritoneal carcinomatosis (PC) can affect the quality of life of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Peritoneal disease control by medical therapies in these patients has been poorly investigated Objectives: To describe, in a consecutive series of GEP-NENs, the clinical impact of PC and to report the effectiveness of available treatments in PC control. Methods: A retrospective, monocenter analysis was performed of 135 GEP-NENs (1993-2016 with at least a 12-month follow-up. Peritoneal disease progression was defined as detection of a significant increase in size or appearance of new implants by imaging. Results: A total of 62.9% of cases had diffuse PC (involving at least 2 abdominal quadrants). According to WHO 2017 classification, cases were 42.3% neuroendocrine tumors NET-G1, 45.5% NET-G2, 6.5% NET-G3, 4.9% neuroendocrine carcinomas NEC-G3, and 0.8% mixed neuroendocrine-nonneuroendocrine neoplasms. Bowel obstruction occurred in 30 (22.2%) patients mainly depending on size of peritoneal implants (HR: 1.10; 95% CI: 1.02-1.20; p = 0.01). Patients with diffuse PC treated with peptide receptor radionuclide therapy (PRRT) showed peritoneal progression in 37.5% of cases, and bowel obstruction or ascites in 28.1%. Better peritoneal disease control was observed in cases receiving somatostatin analogs at first-line therapy, probably due to a less aggressive disease behavior for these patients. Conclusions: Bowel obstruction is not uncommon in GEP-NENs with PC. PRRT should be adopted with caution in GEP-NENs with diffuse PC, but larger series are needed to confirm these data.

show abstract

Neuroendocrine Peritoneal Metastases

Leiting

Grotz

2021

Neuroendocrine Tumors

View full text Add to dashboard Cite

Management of peritoneal metastasis from neuroendocrine tumors

Cited by 7 publications

References 6 publications

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options

Neuroendocrine Peritoneal Metastases

Contact Info

Product

Resources

About